


Eritoran Tetrasodium

Chemical Properties

CAS No. :	185954-98-7
Formula:	C ₆₆ H ₁₂₂ N ₂ Na ₄ O ₁₉ P ₂
Molecular Weight:	1401.58
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Eritoran Tetrasodium, a TLR4 receptor antagonist, is used potentially for the treatment of type 2 diabetes.
Targets(IC50)	Others,Antifection,TLR

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.7135 mL	3.5674 mL	7.1348 mL
5 mM	0.1427 mL	0.7135 mL	1.427 mL
10 mM	0.0713 mL	0.3567 mL	0.7135 mL
50 mM	0.0143 mL	0.0713 mL	0.1427 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Mcdonald KA, Huang H, Tohme S, Loughran P, Ferrero K, Billiar T, Tsung A. Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling. *Mol Med*. 2015 Mar 13;20:639-48. doi: 10.2119/molmed.2014.00076. PubMed PMID: 25375408; PubMed Central PMCID: PMC4365061.

Kuo WT, Lee TC, Yu LC. Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That Bind Lipopolysaccharide. *Cancer Res*. 2016 Aug 15;76(16):4684-95. doi: 10.1158/0008-5472.CAN-16-0172. PubMed PMID: 27328732.

Korff S, Loughran P, Cai C, Lee YS, Scott M, Billiar TR. Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma. *J Surg Res*. 2013 Oct;184(2):e17-25. doi: 10.1016/j.jss.2013.03.023. PubMed PMID: 23777984.

Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL; ACCESS Study Group.. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. *JAMA*. 2013 Mar 20;309(11):1154-62. doi: 10.1001/jama.2013.2194. PubMed PMID: 23512062.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481